Product Description
Tracer for positron emission tomography / computed tomography (PET/CT) scans (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02193672)
Mechanisms of Action: Imaging Agent
Novel Mechanism: No
Modality: Diagnostic Agent
Route of Administration: Injection
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GE Healthcare
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Adenocarcinoma|Colorectal Cancer|Pancreatic Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2018-003522-86 |
18F-Fluciclatide tumor imaging | P2 |
Active, not recruiting |
Adenocarcinoma|Colorectal Cancer|Pancreatic Cancer |
2020-03-21 |
2022-03-13 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|